Our study increases knowledge about involvement of the SP/NK-1R system in glioma and also confirms that the NK1-R is a promising and specific therapeutic target (acting like an Achilles heel) for the treatment of glioma. This evidence concerns the gene TACR1 and central nervous system cancer.